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Summary
Introduction: Klebsiella pneumoniae is of high prevalence in hospital infections,
mainly in bloodstream infections (BSI), and some produce extended-spectrum b-
lactamase (ESBL). For hospitals with a high prevalence of strains producing this
enzyme, there is no reference material to show whether the use of the E-test method
for their detection, which can be quite expensive, is actually required.
Objective: To evaluate the cost-benefit of the disk diffusion and E-test methods for
the detection of ESBL-producing K. pneumoniae strains in hospitals where a high
prevalence of this resistance mechanism in BSI is found.
Methods: One hundred and eight patients with K. pneumoniae BSI were evaluated
retrospectively. ESBL-producing strains were identified by the disk diffusion method
and by the E-test method. We estimated the costs of both diagnostic methods based
on antimicrobial therapy adequacy.
Results: Fifty-two percent of K. pneumoniae infections were due to ESBL-producing
strains. The disk diffusion method yielded a positive predictive value (PPV) of 94.7%
(95% CI: 88.9—100%) and a negative predictive value (NPV) of 96.1% (CI 95%: 90.8—
101.4%) in relation to the E-test. We evaluated cost-effectiveness, i.e., we analyzed
the cost of both E-test and disk diffusion methods with carbapenem and cephalos-
porins, and found that the use of the disk diffusionmethod accounts for approximately
US$3300.* Corresponding author. Tel.: +55 11 5576 4094; fax: +55 11 5576 4094.
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Production of b-lactamases in Gram-negative bac-
teria represents their main mechanism of resistance
to b-lactam antimicrobials. With particular regard
to Klebsiella pneumoniae, greater resistance is
mediated by the extended-spectrum b-lactamases
(ESBL), so-named because of the number of sub-
strates they reach.1
These mutant enzymes provide increased levels
of resistance to cefotaxime, ceftazidime, to the
further extended-spectrum cephalosporins and to
monobactams, such as aztreonam. They show no
activity against cephamycins or imipenem.2
Prevalence of ESBL-producing K. pneumoniae
strains in hospitals ranges from 5 to 25% in several
parts of the world.3—6
The lack of a rapid and effective method of
determining resistance mechanisms and no gold
standard for the detection of ESBL, have made
the rapid administration of suitable antimicrobial
treatment difficult. With regard to hospitals having
a high prevalence of strains producing this enzyme,
there are no studies showing whether the use of the
E-test for their detection, which can be quite expen-
sive, is actually required.
The aim of this study was to determine the cost-
benefits of the disk diffusion and E-test methods for
the detection of ESBL-producing K. pneumoniae
strains in hospitals where a high prevalence of this
resistance mechanism in bloodstream infections
(BSI) is found.Materials and methods
This is a retrospective cohort study, carried out at
the Federal University of Sa˜o Paulo, a 624-bed aca-
demic tertiary care hospital, located in Sa˜o Paulo
State, Brazil. The study took place between January
1996 and May 2001. All patients (the majority being
adults) whose blood culture results were positive for
K. pneumoniae, were eligible for inclusion. We
excluded patients with false bacteremia by K. pneu-
moniae, defined as the presence of positive blood
culture without clinical manifestations of infection,and patients with incomplete data in their medical
charts. Each patient was included only once. If
multiple blood cultures from the same patient were
positive for the above organism, only the first epi-
sode was reviewed and recorded.
Antimicrobial adequacy
Inadequate empiric antimicrobial treatment was
defined as therapy administered within 24 hours
following blood culture, that included the adminis-
tration of an antimicrobial agent to which the K.
pneumoniae isolate was resistant. Antimicrobial
agents were considered adequate if the organism
was susceptible, except when cephalosporins were
used for the treatment of ESBL infections.4 A cor-
rection was defined when the antimicrobial agent
was changed according to the antimicrobial suscept-
ibility test results within 48 hours after the blood
culture had been drawn.
Outcome
Mortality related to bacteremia was considered to
be present when a patient died within fifteen days of
the start of treatment and the death could not be
directly attributed to any other cause.
Microbiological methods
Blood cultures (consisting of two blood culture bot-
tles including aerobic and anaerobic resin-containing
media) obtained from patients were processed using
the BACTEC 9240 blood culture system (Beckton
Dickinson, USA). Growing isolates were identified
according to routine bacteriological procedures.
For every K. pneumoniae sample, a bacterial suspen-
sion in Muller—Hinton broth was performed, to
achieve 0.5 equivalent turbidity on McFarland’s
scale. After homogenization of the suspension, it
was spread on two 15  150 mm Muller—Hinton
agar plates and then the following antimicrobial
disks were placed on the plates: amikacin 30 mg,
aztreonam 30 mg, cephalothin 30 mg, cefepime
30 mg, cephoperazone 75 mg, cefotaxime 30 mg,
cefoxitin 30 mg, ceftazidime 30 mg, ceftriaxoneConclusions: In hospitals with a high prevalence of ESBL-producing strains, the disk
diffusion method can be used to detect ESBL-producing K. pneumoniae without
compromising the clinical progression of patients with BSI. The E-test showed higher
accuracy but this method was more expensive than the disk diffusion method.
However, the use of the E-test method was demonstrated to be more cost-effective,
as we evaluated cost based on antimicrobial therapy adequacy.
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micin 10 mg, imipenem 10 mg andmeropenem 10 mg.
The plates were incubated at 35 8C for 18—
24 hours, and the inhibition zones were then read.
Antimicrobial susceptibility testing was performed
by the disk diffusion method, according to the
Clinical and Laboratory Standards Institute (CLSI,
formerly National Committee for Clinical Labora-
tory Standards — NCCLS).7,8
ESBL detection
The K. pneumoniae strain was considered to have an
ESBL phenotype if it demonstrated a reduced inhibi-
tion zone diameter for ceftazidime (22 mm) or cef-
triaxone (25 mm) or aztreonam (27 mm).
ESBL production was confirmed with the E-test
ESBL strips (AB BIODISK1).9 The E-test ESBL strip
is an inert plastic strip that has an antimicrobial
concentration gradient on both ends of one of its
surfaces. One of the ends has ceftazidime concen-
trations ranging from 0.5 mg/mL to 32 mg/mL and
the other end, ceftazidime with a concentration
gradient ranging from 0.064 mg/mL to 4 mg/mL,
combined with clavulanic acid in a fixed concentra-
tion of 4 mg/mL. E-test ESBL strips containing cefo-
taxime were also used. Like the ceftazidime strip,
the strip containing cefotaxime has a drug concen-
tration gradient on both ends. On one of the ends,
the cefotaxime concentration ranges from 0.25 mg/
mL to 16 mg/mL and on the other end, an increasing
concentration of cefotaxime ranging from 0.016 mg/
mL to 1 mg/mL combined with the fixed 4 mg/mL
concentration of clavulanic acid. The E-test was
considered the gold standard method for the detec-
tion of ESBL-producing strains. Disk diffusion results
achieved by both lab methods were in agreement.
Costs
To detect antimicrobial susceptibility using the disk
diffusion screening method (twelve disks per plate),
US$0.60 was spent per K. pneumoniae strain. To
detect the ESBL-producing K. pneumoniae strains,
two E-test strips were used at a cost of US$10.60.Table 1 Disk diffusion and E-test methods ratio for detect
Disk-diffusion ESBL-suggestive strain
ESBL-non-suggestive strain
Total
n = number of cases; (%) = percentage.For antimicrobial treatment of BSI caused by an
ESBL-producing strain we used for calculation pur-
poses, the standard adult dose for normal renal
function which is 2.0 g imipenem per day for 14
days, corresponding to US$1679.92 per patient trea-
ted. Likewise, we used the same calculation basis
for the antimicrobial treatment of BSI caused by a
non-ESBL producing strain using 2.0 g ceftriaxone
daily for 14 days, corresponding to US$295.96.10
Patients deemed false negative for the production
of ESBL, who were given cephalosporins, we con-
sidered as having been given five days of ceftriaxone
and then 14 days of imipenem, following the
assumptions of Paterson et al.,5 of antimicrobial
therapy failure or death for the patients with BSI
caused by the ESBL-producing strain and not treated
with cephalosporins. We estimated the costs of the
E-test and disk diffusion methods based on antimi-
crobial therapy adequacy (calculations below) and
then the cost difference between the two methods
within the population studied, comparing them to
hospitals with 2, 10, 25 and 52% prevalence of ESBL
strains as shown in our study.
Calculations
Cost of E-test/antimicrobial therapy adequacy =
(cost of E-test  total patients) + (number of ESBL
strains positive  cost of treatment with imipe-
nem) + (number of ESBL strains negative  cost of
treatment with ceftriaxone).
Cost of disk diffusion/antimicrobial adequacy =
(cost of disk diffusion  total patients) + (number of
strains suggestive of ESBL positive  cost of treat-
ment with imipenem) + (number of strains sugges-
tive of ESBL negative  cost of treatment with
ceftriaxone) + (number of false negative case-
s  cost of ceftriaxone for 5 days) + (number of false
positive cases  cost of treatment with imipenem).
Results
During the study period, 115 patients with K. pneu-
moniae BSI isolates were identified, 108 of these
met criteria for inclusion. ESBL production byion of ESBL-producing K. pneumoniae samples.
E-Test
E-test + E-Test  Total
n (%) n (%) n (%)
54 (96.4) 3 (5.8) 57 (52.8)
2 (3.6) 49 (94.2) 51 (47.2)
56 (100) 52 (100) 108 (100)
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Table 2 Disk diffusion with positive and negative
predictive values according to ESBL prevalence.
ESBL Prevalence 2% 10% 25% 52%
PPV (%) 25.4 65.1 85.7 94.7
NPV (%) 99.9 99.6 98.8 96.1
PPV, positive predictive value; NPV, negative predictive value.
Sensitivity = 96.4%, Specificity = 94.2%.K. pneumoniae was present in 51.9% (56/108) of
patients.
The concordance between the disk diffusion and
E-test methods is shown in Table 1 and corresponds
to 95.4% (103/108 cases).
When disk diffusion susceptibility test data were
used to establish the antimicrobial treatment, as
few as 1.9% (2/108) of false negative cases failed to
be adequately treated. Thus, disk-diffusion showed
a positive predictive value (PPV) of 94.7% (95% CI:
88.9—100%) and negative predictive value (NPV) of
96.1% (95% CI: 90.8%—101.4%).
By using different ESBL prevalence values we
were able to find different PPV and similar NPV,
as seen in Table 2.
Antimicrobial therapy was considered adequate
in 63.9% (69/108) of cases, inadequate in 27.8% (30/
108) and adjusted in 8.3% (9/108). The adequacy of
antimicrobial therapy was similar when comparing
ESBL and non-ESBL producing strains of K. pneumo-
niae. Mortality related to K. pneumoniae up to 15
days after the BSI, occurred in 26/108 (24.1%)
patients. In 18 patients (16.7%), death was not
related to K. pneumoniae BSI. The overall mortality
rate if analyzing the full hospitalization period was
40.8%.
Of the five patients presenting with different
results from the disk diffusion and E-test, three
had false positive results, two of which progressed
to death. One of those patients had liver disease and
was given inadequate antibiotic therapy (cephalos-
porin) despite susceptibility test data suggestive of
the ESBL-producing strain; the patient’s death was
related to blood stream infection. The other patient
was a newborn with an insulin hypersecreting
abdominal tumor, hospitalized for eight months
who progressed to non-infection-related death.Table 3 Estimated cost of disk diffusion and E-test methods
with K. pneumoniae blood stream infections according to E
Cost (US$) ESBL Prevalence
2% 10%
E-test 37260.36 4833
Disk-diffusion 44484.12 5555
Cost difference 7223.76 722
Cost difference = E-test method — disk diffusion method (implicit aAlthough disk diffusion showed a high positive
predictive value (94.7%), in an institution with a
high prevalence of the ESBL-producing K. pneumo-
niae strain (52%), we calculated the costs of the
diagnostic methods used for the detection of this
resistance mechanism, i.e., E-test and disk diffu-
sion, by correlating diagnostic costs with the use of
adequate antimicrobial therapy and the prevalence
of this enzyme in other hospitals (Table 3).Discussion
Most studies identify ESBL-producing K. pneumoniae
strains by using the E-test ESBL strips.1,3,4,11,12 In the
present study we show a high prevalence (52%) of
ESBL-producing strains in BSI. Prevalence of ESBL-
producing strains detected by clinical microbiology
laboratories using the E-test methodology ranges
from 5% in Canada, 8% in the United States, to
23% in Europe and 25% in the Pacific western region.3
Paterson et al., in an observational prospective
study involving 12 hospitals in the United States,
Taiwan, Australia, South Africa, Turkey, Belgium and
Argentina, analyzed 455 K. pneumoniae bactere-
mias, detecting 30.8% episodes of nosocomial bac-
teremia caused by ESBL-producing strains, by the E-
test.5 Resistance detection, by using either cefta-
zidime or aztreonam as screening for the detection
of ESBL-producing strains, failed to establish the
diagnosis in 15—20% of cases.11 However, it should
be pointed out that the prevalence of ESBL-produ-
cing strains was less than 25% in those studies.1,2,11
None of the studies correlated the progression of
patients with K. pneumoniae infections according to
the final susceptibility test data by disk diffusion
with the E-test, or evaluated the costs of such
diagnostic methods with adequate antimicrobial
therapy.
We considered the use of carbapenems in all K.
pneumoniae strains thought to be suggestive of ESBL
by disk diffusion, in accordance with Paterson
et al.,6 and found that the use of carbapenems
during the 5-day period after onset of bacteremia
due to an ESBL-producing organism, was indepen-
dently associated with lower mortality.based on antimicrobial therapy adequacy in 108 patients
SBL prevalence.
25% 52%
2.04 70475.40 110610.20
5.80 76420.90 113893.50
3.76 5945.50 3283.28
ntimicrobial therapy adequacy).
60 A.R. Marra et al.By using prevalence of ESBL-producing strainswith
disk diffusion, we found that in institutions with high
prevalence of K. pneumoniae producing that
enzyme, i.e., over 50%, the PPV of the disk diffusion
test is high and therefore, the E-test would not be
required. In our study the two false-negative patients
(1.9%) were inadequately treated using the disk dif-
fusion method. Those two cases did not progress to
death, although we used only third-generation
cephalosporins. On the other hand, if we evaluate
cost-effectiveness, i.e., if we analyze the cost of
both E-test and disk diffusion methods with the
adequate use of carbapenem and cephalosporins,
in this 108-patient population, we find that approxi-
mately US$3300 is spent when the disk diffusion
method is used. In sites of low prevalence of ESBL-
producing K. pneumoniae, the disk diffusion test
shows a low PPV (Table 2) and even increased cost-
effectiveness, approximately US$7200, if disk diffu-
sion is not used (Table 3). This is because the false
positive cases are treated with carbapenem agents,
with a 14-day treatment cost of approximately
US$1680. In our study, we had three cases, i.e., an
excess cost of US$5040. If there had been no false
positives, these cases would have been treated with
cephalosporins (ceftriaxone, for the calculation) and
US$888 would have been spent, thus saving US$4152.
The above means that the cost of adequate treat-
ment with carbapenems extends beyond the cost of
the diagnostic method for the detection of ESBL-
producing strains.
On the other hand, we could have used a con-
firmed test (with clavulanate disk) for ESBL produ-
cing strains.7 It would be able to detect false-
positive cases in the same way as the E-test, how-
ever it would not increase the sensitivity of the test.
It could be used as another alternative to the E-test
and the cost would be lower, but we believe that the
sensitivity is higher with the E-test method.
In conclusion, disk diffusion may guide appropri-
ate antimicrobial treatment of blood stream infec-
tions caused by ESBL-producing K. pneumoniae in
hospitals with a high prevalence of this resistance
mechanism. However, although the E-test is an
expensive laboratory method, when we evaluated
cost based on antimicrobial therapy adequacy,
cost-effectiveness accounted for US$3300 when
patient treatment was guided by this method, as
compared to the disk diffusion method. Thus, for
adequate treatment of patients with BSI due to K.pneumoniae, performance of the E-test screening is
justified.
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